We examined factors associated with selection of initial antiretroviral regimen in the CNICS cohort. Patients initiating antiretroviral therapy (ART) between July 2009 and Dec 2012 were classified as receiving an NNRTI, boosted-PI, or raltegravir-based regimen. Among 873 patients initiating ART, 488 regimens contained an NNRTI, 319 a boosted-PI, and 66 raltegravir. Patients with depression and women were less likely to receive an NNRTI, while those with underlying cardiovascular disease, liver disease, and those co-infected with hepatitis C were more likely to receive raltegravir. Those with baseline viral load > 100,000 c/ml and those with substance use were more likely to receive a boosted PI. Thus, in the ‘real world’ ARV regimen choices appear to take into account adverse effects and patient baseline characteristics. Factors that impact initial regimen selection will likely become more heterogeneous over time as more choices for HIV therapy become available.
Methods With various levels of depression, as according to the Centre for Epidemiological Studies-Depression (CES-D) scale, 88 HIV newly diagnosed subjects were enrolled in the study. After 6-month intervention of case management, their depression status were re-evaluated and compared. Results No significant differences for depression status were found 6 months after the intervention of case management among study subjects (p = 0.345). However, the results of linear regression analysis indicated that those who had family support (beta = 0.303, p = 0.012) and lower HIV viral load (beta =-0.265, p = 0.041) would have better improvement for depression. Conclusion Our findings indicate case management offers no apparent help lowering depression among PLWHA. However, HIV case managers should remind and assist physicians to paying more attention to PLWHA with lower family support or higher HIV viral load to avoid depression symptoms happened. Disclosure of interest statement The Australasian Society for HIV Medicine recognises the considerable contribution that industry partners make to professional and research activities. We also recognise the need for transparency of disclosure of potential conflicts of interest by acknowledging these relationships in publications and presentations. Nothing to declare.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.